SCHEMBL5715669

SCHEMBL5715669

CC(Sc1ncc[nH]1)c1ccc(OC(=O)N2CCN(c3ccc(CC(=O)O)cn3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 6/20 0.48
HRH3 Q9Y5N1 2/20 0.38
NPSR1 Q6W5P4 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 2/20 0.37
MAPK1 P28482 2/20 0.37
CYP2C19 P33261 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
GPR119 Q8TDV5 4/20 0.37
ME2 P23368 3/20 0.36
ME1 P48163 3/20 0.36
ME3 Q16798 3/20 0.36
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715048 0.87 PANK3 (0.50) PANK3HRH3NPSR1CYP1A2CYP2C9
SCHEMBL5715243 0.87 PANK3 (0.52) PANK3HRH3CYP1A2CYP2C9MAPK1
SCHEMBL5715494 0.86 PANK3 (0.53) PANK3HRH3LMNAHSD17B10SMN1; SMN2
SCHEMBL5715127 0.86 PANK3 (0.51) PANK3HRH3HPGDSMN1; SMN2
SCHEMBL5715000 0.85 PANK3 (0.41) PANK3HRH3NPSR1CYP1A2CYP2C9
SCHEMBL5716315 0.84 SMN1; SMN2 (0.52) PANK3HRH3CYP1A2CYP2C9CYP2C19
SCHEMBL5904372 0.84 PANK3 (0.40) PANK3NPSR1CYP1A2CYP2C9MAPK1
SCHEMBL5715343 0.84 HSD17B10 (0.49) PANK3HRH3NPSR1CYP1A2CYP2C9
SCHEMBL5690454 0.83 EPHX2 (0.41) HRH3LMNAGPR119ALDH1A1
SCHEMBL5904323 0.82 PANK3 (0.46) PANK3HRH3NPSR1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC PANK3 1247/4885HRH3 1098/4885NPSR1 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.